BeyondSpring Inc. presented interim Phase 2 data from its 303 Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2025. The study evaluated a triple combination regimen of Plinabulin, pembrolizumab, and docetaxel in 47 patients with second- and third-line metastatic non-small cell lung cancer (NSCLC) who had progressed on first-line PD-1/L1 inhibitors.
The data, with a median follow-up of 12.7 months as of the May 16, 2025, cut-off date, reinforced Plinabulin’s potential to address acquired resistance to checkpoint inhibitors. The company highlighted that Plinabulin aims to restore immune sensitivity and improve progression-free survival, disease control rate, and overall survival in this difficult-to-treat patient population.
Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, emphasized that Plinabulin's mechanism of activating dendritic cell maturation and T cell activation offers a new therapeutic path for patients who stop responding to PD-1/L1 therapies. The study also noted Plinabulin's benefit in significantly reducing severe neutropenia associated with docetaxel.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.